| 32K |
| $1.2M |
| — |
| 0.064% |
| 0.00% |
| 4 | XTX Topco Ltd | 16K | $598K | — | 0.031% | 0.01% |
| 5 | Optiver Holding B.V. | 14K | $514K | +1.0% | 0.027% | 0.00% |
| 6 | MARSHALL WACE, LLP | 10K | $379K | +8.7% | 0.020% | 0.00% |
| 7 | CITADEL ADVISORS LLC | 6K | $228K | — | 0.012% | 0.00% |
| 8 | BNP PARIBAS FINANCIAL MARKETS | 4K | $152K | +13.6% | 0.008% | 0.00% |
| 9 | UBS Group AG | 3K | $97K | -53.6% | 0.005% | 0.00% |
| 10 | ROYAL BANK OF CANADA | 2K | $83K | +20.0% | 0.004% | 0.00% |
| 11 | JPMORGAN CHASE & CO | 2K | $61K | — | 0.003% | 0.00% |
| 12 | RHUMBLINE ADVISERS | 2K | $57K | -34.2% | 0.003% | 0.00% |
| 13 | GAMMA Investing LLC | 985 | $37K | +19.0% | 0.002% | 0.00% |
| 14 | OSAIC HOLDINGS, INC. | 500 | $19K | 0.0% | 0.001% | 0.00% |
| 15 | WELLS FARGO & COMPANY/MN | 200 | $8K | 0.0% | 0.000% | 0.00% |
| 16 | Stone House Investment Management, LLC | 76 | $3K | — | 0.000% | 0.00% |
| 17 | Federation des caisses Desjardins du Quebec | 56 | $2K | — | 0.000% | 0.00% |
| 18 | HRT FINANCIAL LP | 27K | $1K | — | 0.054% | 0.00% |
| 19 | NATIONAL BANK OF CANADA /FI/ | 13 | $482 | 0.0% | 0.000% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in NBTX — a direct measure of their conviction.
| 11.39% |
| 0.60 pp |
| $21M |
| +18% |
| Q4 2024 | 19 | +73% | 11.99% | 0.69 pp | $17M | 53% |
| Q3 2024 | 11 | — | 12.68% | — | $37M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
6 institutions opened new positions in NBTX during Q2 2026, while 3 fully exited. 10 added to existing positions and 2 trimmed.
NBTX institutional ownership rose by 0.19 percentage points quarter-over-quarter, with a net change of +4 holders.
The top 10 institutions account for 99.9% of all reported 13F value in NBTX, and the top 25 account for 100.0%.
Across the largest Oncology Biotech peers, institutional ownership levels are: DMRA (200.0%), FTH (54.5%), LONA (184.4%), KYNB (26.9%), CNSY (4.8%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.